FDA’s approval of Eli Lilly & Co.’s Cymbalta (duloxetine) for treatment of fibromyalgia sets another precedent in the new era of Risk Evaluation & Mitigation Strategies: the agency will not necessarily seek a formal REMS for products already accompanied by mandatory medication guides.
Cymbalta received FDA approval for the new indication on June 13. Like all antidepressants, duloxetine carries a boxed warning in...





